Richard Auchus, MD, PhD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Novartis Pharmaceuticals
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Neurocrine Biosciences
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Spruce Biosciences
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Corcept Therapeutics
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Diurnal, LTD
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Quest Diagnostics
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Corcept Therapeutics
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Janssen Pharmaceuticals
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Novartis Pharmaceuticals
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025
  • Attribution: 
    Self
    Type of financial relationship: 
    Independent contractor
    Ineligible company: 
    Strongbridge Biopharma/Xeris Pharmaceuticals
    Date added: 
    06/06/2022
    Relationship end date: 
    12/31/2025

Pages

Return to 2nd Annual UT Southwestern Multidisciplinary Endocrine Tumor Symposium: Mild Autonomous Cortisol Secretion And Primary Aldosteronism (RP2206E)